The last worldwide evaluation on HCC impact and alarm refer to 20121 with dramatic information in term of incidence rate and survival outcome. Despite the fact that more than 6 years are passed, the HCC represents, still nowadays, one of the main oncological diseases in terms of incidence and negative survival rate with worrying incidence also in many industrialized countries2 . Scientific evidence highlights how antioxidant3 as well as nutraceutical agents4 can reduce the risk to develop the HCC, but it is not enough in order to fight its progression and metastasis5 . Several mechanisms of action and markers were discovered for the HCC6 , laying the foundations of the future innovative therapies and diagnosis approaches. In this scenario, we read with great interest the article of Zhang et al7 . They evaluated and disseminated the role of the LncRNA SBF2-AS1 in HCC patients. Starting from patients’ data, they focus on the LncRNA SBF2- AS1 levels via bioinformatics and qPCR approaches. The data outcome correlates with the SBF2-AS1 up regulation in HCC. Moreover, the authors investigated the clinical features and prognosis in HCC patients in correlation with the SBF2-AS1 levels. Vein invasion and TNM stage, together with the low survival rate strongly correlate with the high levels of LncRNA SBF2-AS1. On the other hands, the suppression of SBF2- AS1 directly reduces the HCC proliferation and invasion acting on EMT pathway. The Zhang et al7 paper is oriented towards the new frontiers of precision medicine passing by the patients stratification8 . The final goal of last decade oncology research aims to provide the right therapy to the right patient9,10. Concerning the fact the LncRNAs associated with HCC molecular mechanisms is grooving11, the LncRNA SBF2-AS1 should be considered pivotal for as possible new diagnostic marker and therapy in HCC patient. Indeed SBF2-AS1 could represent a new source as druggable target able for innovative HCC treatment. Future studies12 should try to elucidate the potential interplay of mechanism in HCC initiation, progression and fate among the genetic and epigenetic mechanisms.
Comment on: LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis
Franci, G.;
2019-01-01
Abstract
The last worldwide evaluation on HCC impact and alarm refer to 20121 with dramatic information in term of incidence rate and survival outcome. Despite the fact that more than 6 years are passed, the HCC represents, still nowadays, one of the main oncological diseases in terms of incidence and negative survival rate with worrying incidence also in many industrialized countries2 . Scientific evidence highlights how antioxidant3 as well as nutraceutical agents4 can reduce the risk to develop the HCC, but it is not enough in order to fight its progression and metastasis5 . Several mechanisms of action and markers were discovered for the HCC6 , laying the foundations of the future innovative therapies and diagnosis approaches. In this scenario, we read with great interest the article of Zhang et al7 . They evaluated and disseminated the role of the LncRNA SBF2-AS1 in HCC patients. Starting from patients’ data, they focus on the LncRNA SBF2- AS1 levels via bioinformatics and qPCR approaches. The data outcome correlates with the SBF2-AS1 up regulation in HCC. Moreover, the authors investigated the clinical features and prognosis in HCC patients in correlation with the SBF2-AS1 levels. Vein invasion and TNM stage, together with the low survival rate strongly correlate with the high levels of LncRNA SBF2-AS1. On the other hands, the suppression of SBF2- AS1 directly reduces the HCC proliferation and invasion acting on EMT pathway. The Zhang et al7 paper is oriented towards the new frontiers of precision medicine passing by the patients stratification8 . The final goal of last decade oncology research aims to provide the right therapy to the right patient9,10. Concerning the fact the LncRNAs associated with HCC molecular mechanisms is grooving11, the LncRNA SBF2-AS1 should be considered pivotal for as possible new diagnostic marker and therapy in HCC patient. Indeed SBF2-AS1 could represent a new source as druggable target able for innovative HCC treatment. Future studies12 should try to elucidate the potential interplay of mechanism in HCC initiation, progression and fate among the genetic and epigenetic mechanisms.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
